Mabwell's incubated firm, SynuSight Biotech, has secured NMPA approval to conduct Phase I trials for its promising α-syn PET tracer, SST001.

SHANGHAI, April 15, 2026 /PRNewswire/ — Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that 18F-FD4 (R&D code: SST001), an α-synuclein (α-syn) targeted PET tracer independently developed by its incubated company SynuSight Biotech, has recently been approved by the National Medical Products Administration (NMPA) to initiate a Phase I clinical […]